Regional and intratumoral adoptive T-cell therapy

Area of Science:

• Immunology
• Oncology
• Cell Therapy

Background:

• Adoptive T-cell therapies (ACTs) are effective against blood cancers but face challenges in solid tumors.
• Limited lymphocyte access to solid tumors hinders ACT efficacy.
• Regional administration strategies are being explored to overcome these barriers.

Purpose of the Study:

• To review the preclinical and clinical landscape of regional adoptive T-cell therapies for solid tumors.
• To discuss strategies for improving T-cell activity and overcoming delivery challenges.
• To highlight areas for future research and optimization.

Main Methods:

• Review of preclinical and clinical studies on regional ACT delivery (intratumoral, intracavitary).
• Discussion of strategies to enhance T-cell function and overcome tumor microenvironment barriers.
• Analysis of ongoing clinical trials and future research directions.

Main Results:

• Regional ACT delivery, including intralesional and intracavitary routes, shows promising antitumor responses in preclinical and clinical studies.
• Strategies like combining ACTs with other immunotherapies or engineering T cells aim to improve efficacy and immune memory.
• Ongoing trials are evaluating various regional ACT approaches.

Conclusions:

• Regional administration of ACTs is a promising strategy to enhance T-cell infiltration and activity in solid tumors.
• Further optimization of administration methods and target antigen selection is crucial to minimize side effects and maximize therapeutic benefit.
• Continued research and clinical trials are essential to advance regional ACTs for cancer treatment.